AOH 1996
Alternative Names: AOH-1996Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator City of Hope National Medical Center
- Developer City of Hope National Medical Center; RLL LLC
- Class Antineoplastics; Small molecules
- Mechanism of Action Proliferating cell nuclear antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 02 Jan 2025 City of Hope Medical Center plans a phase I/Ib for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy, Recurrent) in USA(PO) in August 2025 (NCT06763341)
- 10 Dec 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to December 2024
- 10 Dec 2024 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia released by City of Hope National Medical Center